Nearly one quarter of lung cancer patients respond to Merck’s cancer drug – MedCity News

by lowes1 on October 7, 2013

Nearly one quarter of lung cancer patients respond to Merck's cancer drug
MedCity News
(Reuters) – Early data from a small trial of Merck & Co Inc's experimental immunotherapy cancer drug, known as MK-3475, showed that about a quarter of lung cancer patients responded to the treatment. Data from the trial is slated for presentation in

and more »

View full post on lung cancer – Google News

Leave a Comment

Previous post:

Next post: